FASENRA® (benralizumab) Mechanism of Action | For HCPs
Learn about FASENRA® (benralizumab) and its mechanism of action. FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
Benralizumab: From the Basic Mechanism of Action to the ...
Mechanisms of action of benralizumab. Via its Fab fragments, the humanized monoclonal antibody benralizumab specifically binds to IL-5Rα, thereby preventing the interaction between IL-5 and its receptor.
FASENRA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 3 doses, and then every 8 weeks thereafter. Table 1. Recommended...
EGPA | Mechanism of Action | FASENRA® (benralizumab) | For …
Learn about the FASENRA mechanism of action, and its potential impact on EGPA treatment. FASENRA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype.
Benralizumab: Uses, Interactions, Mechanism of Action ...
2016年10月20日 · Mechanism of action. The pathology of severe asthma with eosinophilic phenotype is called the TH2-high phenotype. Patients with this phenotype are characterized by the expression of IL-5 and IL-13, airway hyperresponsiveness, responsiveness to inhaled corticosteroids, high serum IgE, and eosinophilia in the blood and airways.
Benralizumab in Severe Asthma - Centre of Excellence in ...
2020年3月13日 · Benralizumab (Fasenra) is indicated as an add-on therapy for people with uncontrolled severe eosinophilic asthma, aged ≥12 years. Benralizumab is an IgG1 antibody directed against the interleukin 5 receptor-alpha (IL-5Ra). IL-5 is a major cytokine responsible for the growth, differentiation, recruitment, activation and survival of eosinophils.
FASENRA is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and...
DailyMed - FASENRA- benralizumab injection, solution
2024年4月5日 · 12.1 Mechanism of Action Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with a dissociation constant of 11 pM.
What is Fasenra used for and how does it work? - Drugs.com
2024年10月4日 · Fasenra's mechanism of action (MOA) involves specifically targeting eosinophils, which are white blood cells associated with inflammation found in the airways of people with asthma and tissues of people with EGPA.
Executive Summary - Clinical Review Report: Benralizumab ...
2018年2月22日 · Benralizumab is an interleukin-5 (IL-5) inhibitor, a monoclonal antibody that binds to the alpha subunit of the IL-5 receptor. The IL-5 alpha receptor is found on eosinophils and basophils. Binding of the monoclonal antibody facilitates the interaction of these cells with natural killer cells, resulting in the death of eosinophils.